[Correspondence] GLP-1 receptor agonists for obesity: eligibility across 99 countries

Obesity is a complex, multifactorial condition defined by excessive adiposity and associated health risks.1 The rising prevalence of obesity contributes to the increasing global burden of obesity-related diseases, such as type 2 diabetes and cardiovascular diseases, placing immense strain on health-care systems and economies worldwide. Behavioural interventions, such as diet and exercise, have long been the foundation of obesity management, yet many individuals face challenges in achieving and maintaining substantial long-term weight loss through these approaches alone, especially in current obesogenic environments.